Cargando…

The usefulness of soluble receptor for advanced glycation end-products in the identification of COPD frequent exacerbator phenotype

INTRODUCTION: Exacerbations of COPD (ECOPDs) are important events in the course of COPD, accelerating the rate of decline in lung function and increasing the mortality risk. A growing body of evidence suggests the significance of the “frequent exacerbator” phenotype. This phenotype seems to be assoc...

Descripción completa

Detalles Bibliográficos
Autores principales: Miłkowska-Dymanowska, Joanna, Białas, Adam J, Szewczyk, Karolina, Kurmanowska, Zofia, Górski, Paweł, Piotrowski, Wojciech J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6276626/
https://www.ncbi.nlm.nih.gov/pubmed/30568439
http://dx.doi.org/10.2147/COPD.S186170
_version_ 1783378045811294208
author Miłkowska-Dymanowska, Joanna
Białas, Adam J
Szewczyk, Karolina
Kurmanowska, Zofia
Górski, Paweł
Piotrowski, Wojciech J
author_facet Miłkowska-Dymanowska, Joanna
Białas, Adam J
Szewczyk, Karolina
Kurmanowska, Zofia
Górski, Paweł
Piotrowski, Wojciech J
author_sort Miłkowska-Dymanowska, Joanna
collection PubMed
description INTRODUCTION: Exacerbations of COPD (ECOPDs) are important events in the course of COPD, accelerating the rate of decline in lung function and increasing the mortality risk. A growing body of evidence suggests the significance of the “frequent exacerbator” phenotype. This phenotype seems to be associated with a more severe airflow limitation, symptoms, health-related quality of life impairment, and higher mortality. However, there is no described biomarker that would help to identify this group of patients. PATIENTS AND METHODS: Patients with COPD in “D” GOLD category were monitored for 3 years according to events of ECOPD. Serum samples were collected from the patients. Circulating level of plasma soluble receptor for advanced glycation end-products (sRAGE) was measured using commercially available high sensitivity kits. The receiver operating characteristic (ROC) curve analysis was used to assess the usefulness of sRAGE to identify frequent exacerbator phenotype. Log-rank test was used in the analysis of time to the subsequent exacerbation. Pearson (R) or Spearman’s rank (R(S)) correlation coefficients were used for correlation analysis. RESULTS: Nineteen patients were enrolled. The area under the ROC curve (AUROC) for sRAGE for the identification of frequent exacerbator phenotype was 0.81. Analysis identified the cutoff point as 850.407 pg/mL, characterized by a sensitivity of 0.80 (95% CI: 0.28–1.0) and specificity of 0.93 (95% CI: 0.66–1.0). Additionally, in the group with sRAGE ≤850.407 pg/mL, we observed significantly shorter time to the subsequent exacerbation: median of 32 vs 105.5 days (P=0.03). Correlation analysis revealed significant negative correlation between sRAGE and the number of exacerbations requiring hospitalization during the whole time of follow-up (R(S)=−0.53; P=0.02) and significant positive correlation with FEV(1) expressed as the percentage of reference value (R=0.6; P=0.006). CONCLUSION: sRAGE seems to be useful in the identification of frequent exacerbator phenotype. This parameter may also be used in the prediction of time to ECOPD. Our findings should be confirmed in a sufficiently powered larger sample.
format Online
Article
Text
id pubmed-6276626
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-62766262018-12-19 The usefulness of soluble receptor for advanced glycation end-products in the identification of COPD frequent exacerbator phenotype Miłkowska-Dymanowska, Joanna Białas, Adam J Szewczyk, Karolina Kurmanowska, Zofia Górski, Paweł Piotrowski, Wojciech J Int J Chron Obstruct Pulmon Dis Short Report INTRODUCTION: Exacerbations of COPD (ECOPDs) are important events in the course of COPD, accelerating the rate of decline in lung function and increasing the mortality risk. A growing body of evidence suggests the significance of the “frequent exacerbator” phenotype. This phenotype seems to be associated with a more severe airflow limitation, symptoms, health-related quality of life impairment, and higher mortality. However, there is no described biomarker that would help to identify this group of patients. PATIENTS AND METHODS: Patients with COPD in “D” GOLD category were monitored for 3 years according to events of ECOPD. Serum samples were collected from the patients. Circulating level of plasma soluble receptor for advanced glycation end-products (sRAGE) was measured using commercially available high sensitivity kits. The receiver operating characteristic (ROC) curve analysis was used to assess the usefulness of sRAGE to identify frequent exacerbator phenotype. Log-rank test was used in the analysis of time to the subsequent exacerbation. Pearson (R) or Spearman’s rank (R(S)) correlation coefficients were used for correlation analysis. RESULTS: Nineteen patients were enrolled. The area under the ROC curve (AUROC) for sRAGE for the identification of frequent exacerbator phenotype was 0.81. Analysis identified the cutoff point as 850.407 pg/mL, characterized by a sensitivity of 0.80 (95% CI: 0.28–1.0) and specificity of 0.93 (95% CI: 0.66–1.0). Additionally, in the group with sRAGE ≤850.407 pg/mL, we observed significantly shorter time to the subsequent exacerbation: median of 32 vs 105.5 days (P=0.03). Correlation analysis revealed significant negative correlation between sRAGE and the number of exacerbations requiring hospitalization during the whole time of follow-up (R(S)=−0.53; P=0.02) and significant positive correlation with FEV(1) expressed as the percentage of reference value (R=0.6; P=0.006). CONCLUSION: sRAGE seems to be useful in the identification of frequent exacerbator phenotype. This parameter may also be used in the prediction of time to ECOPD. Our findings should be confirmed in a sufficiently powered larger sample. Dove Medical Press 2018-11-29 /pmc/articles/PMC6276626/ /pubmed/30568439 http://dx.doi.org/10.2147/COPD.S186170 Text en © 2018 Miłkowska-Dymanowska et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Short Report
Miłkowska-Dymanowska, Joanna
Białas, Adam J
Szewczyk, Karolina
Kurmanowska, Zofia
Górski, Paweł
Piotrowski, Wojciech J
The usefulness of soluble receptor for advanced glycation end-products in the identification of COPD frequent exacerbator phenotype
title The usefulness of soluble receptor for advanced glycation end-products in the identification of COPD frequent exacerbator phenotype
title_full The usefulness of soluble receptor for advanced glycation end-products in the identification of COPD frequent exacerbator phenotype
title_fullStr The usefulness of soluble receptor for advanced glycation end-products in the identification of COPD frequent exacerbator phenotype
title_full_unstemmed The usefulness of soluble receptor for advanced glycation end-products in the identification of COPD frequent exacerbator phenotype
title_short The usefulness of soluble receptor for advanced glycation end-products in the identification of COPD frequent exacerbator phenotype
title_sort usefulness of soluble receptor for advanced glycation end-products in the identification of copd frequent exacerbator phenotype
topic Short Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6276626/
https://www.ncbi.nlm.nih.gov/pubmed/30568439
http://dx.doi.org/10.2147/COPD.S186170
work_keys_str_mv AT miłkowskadymanowskajoanna theusefulnessofsolublereceptorforadvancedglycationendproductsintheidentificationofcopdfrequentexacerbatorphenotype
AT białasadamj theusefulnessofsolublereceptorforadvancedglycationendproductsintheidentificationofcopdfrequentexacerbatorphenotype
AT szewczykkarolina theusefulnessofsolublereceptorforadvancedglycationendproductsintheidentificationofcopdfrequentexacerbatorphenotype
AT kurmanowskazofia theusefulnessofsolublereceptorforadvancedglycationendproductsintheidentificationofcopdfrequentexacerbatorphenotype
AT gorskipaweł theusefulnessofsolublereceptorforadvancedglycationendproductsintheidentificationofcopdfrequentexacerbatorphenotype
AT piotrowskiwojciechj theusefulnessofsolublereceptorforadvancedglycationendproductsintheidentificationofcopdfrequentexacerbatorphenotype
AT miłkowskadymanowskajoanna usefulnessofsolublereceptorforadvancedglycationendproductsintheidentificationofcopdfrequentexacerbatorphenotype
AT białasadamj usefulnessofsolublereceptorforadvancedglycationendproductsintheidentificationofcopdfrequentexacerbatorphenotype
AT szewczykkarolina usefulnessofsolublereceptorforadvancedglycationendproductsintheidentificationofcopdfrequentexacerbatorphenotype
AT kurmanowskazofia usefulnessofsolublereceptorforadvancedglycationendproductsintheidentificationofcopdfrequentexacerbatorphenotype
AT gorskipaweł usefulnessofsolublereceptorforadvancedglycationendproductsintheidentificationofcopdfrequentexacerbatorphenotype
AT piotrowskiwojciechj usefulnessofsolublereceptorforadvancedglycationendproductsintheidentificationofcopdfrequentexacerbatorphenotype